152 related articles for article (PubMed ID: 35184255)
1. Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies.
Paterson DL; Kinoshita M; Baba T; Echols R; Portsmouth S
Infect Dis Ther; 2022 Apr; 11(2):853-870. PubMed ID: 35184255
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Timsit JF; Paul M; Shields RK; Echols R; Baba T; Yamano Y; Portsmouth S
Clin Infect Dis; 2022 Sep; 75(6):1081-1084. PubMed ID: 35148378
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
[TBL] [Abstract][Full Text] [Related]
7. Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation.
Portsmouth S; Echols R; Toyoizumi K; Tillotson G; Nagata TD
Ther Adv Infect Dis; 2021; 8():20499361211058257. PubMed ID: 34868583
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Nordmann P; Shields RK; Doi Y; Takemura M; Echols R; Matsunaga Y; Yamano Y
Microb Drug Resist; 2022 Apr; 28(4):398-407. PubMed ID: 35076335
[TBL] [Abstract][Full Text] [Related]
9. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
10. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).
Naseer S; Weinstein EA; Rubin DB; Suvarna K; Wei X; Higgins K; Goodwin A; Jang SH; Iarikov D; Farley J; Nambiar S
Clin Infect Dis; 2021 Jun; 72(12):e1103-e1111. PubMed ID: 33393598
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
13. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
Skaar EP; Echols R; Matsunaga Y; Menon A; Portsmouth S
Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):467-476. PubMed ID: 35025025
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria.
Silva JT; López-Medrano F
Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):41-43. PubMed ID: 34598424
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Ong'uti S; Czech M; Robilotti E; Holubar M
Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
[TBL] [Abstract][Full Text] [Related]
16. Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
Bassetti M; Ariyasu M; Binkowitz B; Nagata TD; Echols RM; Matsunaga Y; Toyoizumi K; Doi Y
Infect Drug Resist; 2019; 12():3607-3623. PubMed ID: 31819544
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia.
Plaisance CJ; Borne GE; Daniel CP; Wagner MJ; Shelvan A; Mathew J; Ahmadzadeh S; Paladini A; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2024 Jan; 16(1):e52230. PubMed ID: 38352089
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.
Cercenado E; Cardenoso L; Penin R; Longshaw C; Henriksen AS; Pascual A
J Glob Antimicrob Resist; 2021 Sep; 26():292-300. PubMed ID: 34274538
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Echols R; Ariyasu M; Nagata TD
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S559-S564. PubMed ID: 31724048
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy.
Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S
J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
